AR098140A2 - Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene - Google Patents

Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene

Info

Publication number
AR098140A2
AR098140A2 ARP140103952A ARP140103952A AR098140A2 AR 098140 A2 AR098140 A2 AR 098140A2 AR P140103952 A ARP140103952 A AR P140103952A AR P140103952 A ARP140103952 A AR P140103952A AR 098140 A2 AR098140 A2 AR 098140A2
Authority
AR
Argentina
Prior art keywords
expression
construction
regulating
nucleotide
preparing
Prior art date
Application number
ARP140103952A
Other languages
English (en)
Inventor
Nguyen Tam
Shanklin John
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of AR098140A2 publication Critical patent/AR098140A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para regular la expresión de un blanco, que comprende proveer a una célula la construcción de nucleótido que comprende: una secuencia de nucleótido que forma un tronco (stem) y un giro (loop); en donde el giro comprende una primera secuencia de nucleótido que modula la expresión de un blanco; en donde el tronco comprende una segunda secuencia de nucleótido que modula la expresión de un blanco; y en donde el blanco modulado por la primera secuencia de nucleótido y el blanco modulado por la segunda secuencia de nucleótido pueden ser iguales o diferentes; y cultivar dicha célula. Se describe también un método para tratar una condición patológica vectores, métodos para regular la expresión del blanco, para preparar una construcción para regular un blanco, composiciones farmacéuticas y células que comprende la construcción de nucleótido utilizada en los métodos.
ARP140103952A 2007-03-21 2014-10-21 Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene AR098140A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89621207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
AR098140A2 true AR098140A2 (es) 2016-05-04

Family

ID=39766774

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080101204A AR066194A1 (es) 2007-03-21 2008-03-25 Composiciones antisentido en horquilla combinadas y metodos para modular la expresion de un gen blanco en celulas
ARP110100994A AR080722A2 (es) 2007-03-21 2011-03-23 Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica
ARP140103952A AR098140A2 (es) 2007-03-21 2014-10-21 Método para regular la expresión de un blanco con una construcción de nucleótidos y para tratar una condición patológica; método para preparar dicha construcción composición médica y célula que la contiene

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP080101204A AR066194A1 (es) 2007-03-21 2008-03-25 Composiciones antisentido en horquilla combinadas y metodos para modular la expresion de un gen blanco en celulas
ARP110100994A AR080722A2 (es) 2007-03-21 2011-03-23 Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica

Country Status (13)

Country Link
US (2) US8796442B2 (es)
EP (1) EP2129680B1 (es)
JP (1) JP5759673B2 (es)
AR (3) AR066194A1 (es)
AU (1) AU2008228814B2 (es)
BR (1) BRPI0809130A8 (es)
CA (1) CA2681323A1 (es)
DK (1) DK2129680T3 (es)
ES (1) ES2538217T3 (es)
HU (1) HUE027018T2 (es)
PL (1) PL2129680T3 (es)
PT (1) PT2129680E (es)
WO (1) WO2008116094A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2129680T3 (en) 2007-03-21 2015-08-10 Brookhaven Science Ass Llc COMBINED hairpin ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF
WO2009140374A2 (en) * 2008-05-13 2009-11-19 Gen-Probe Incorporated Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
US20130136727A1 (en) * 2009-11-19 2013-05-30 President And Fellows Of Harvard College Angiogenin and Variants Thereof for Treatment of Neurodegenerative Diseases
PT2933333T (pt) 2010-07-08 2018-04-24 Bonac Corp Molécula de ácido nucleico de cadeia simples para controlar a expressão génica
CN104059911B (zh) * 2010-08-03 2017-01-04 株式会社博纳克 具有含氮脂环式骨架的单链核酸分子
RU2013129999A (ru) 2010-12-02 2015-01-10 Дайити Санкио Компани, Лимитед Модифицированный одноцепочечный полинуклеотид
CN109810977A (zh) 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
WO2015099187A1 (ja) 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
US11027023B2 (en) 2014-12-27 2021-06-08 Bonac Corporation Natural type miRNA for controlling gene expression, and use of same
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
US20220275381A1 (en) * 2019-08-02 2022-09-01 Commonwealth Scientific And Industrial Research Organisation Rna molecules for modulating flowering in plants

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
DE69133511T2 (de) * 1990-08-13 2006-09-28 Isis Pharmaceuticals, Inc., Carlsbad Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
US6653458B1 (en) * 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
GB9710475D0 (en) * 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US5952657A (en) * 1997-08-22 1999-09-14 Thermo Microscopes, Corp. Atomic force microscope with integrated optics for attachment to optical microscope
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
AU760041B2 (en) 1998-04-08 2003-05-08 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US6106982A (en) 1998-05-11 2000-08-22 Avery Dennison Corporation Imaged receptor laminate and process for making same
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6160215A (en) 1999-03-26 2000-12-12 Curtin; Lawrence F. Method of making photovoltaic device
CA2370628A1 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
IL147026A0 (en) 1999-07-09 2002-08-14 American Home Prod Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
AU1767301A (en) 1999-11-29 2001-06-04 Cold Spring Harbor Laboratory Regulation of polycomb group gene expression for increasing seed size in plants
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
IT1316982B1 (it) 2000-01-17 2003-05-26 Univ Roma Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi.
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
JP2003527856A (ja) 2000-03-17 2003-09-24 ベニテック オーストラリア リミテッド 遺伝子のサイレンシング
WO2001070944A2 (de) 2000-03-22 2001-09-27 Aventis Pharma Deutschland Gmbh Nematoden als modellorganismen zur untersuchung neurodegenerativer erkrankungen und insbesonder der parkinsonschen erkrankung, verwendungen und verfahren zum auffinden von substanzen und genen, die bei der behandlung solcher erfrankungen eingesetz werden können, sowie identifizierung eines nematodengens.
GB0007268D0 (en) 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins
JP4901051B2 (ja) 2000-05-30 2012-03-21 ジョンソン アンド ジョンソン リサーチ プロプライアトリー リミテッド ＲＮＡｉを増強する因子を使用することによって遺伝子抑制を媒介する方法
EP1334123B1 (en) 2000-11-09 2008-08-20 Cenix Bioscience GmbH Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US6566524B2 (en) * 2001-12-21 2003-05-20 The Procter & Gamble Co. Methods for synthesis of amino-tetrahydroisoquinoline-sulfonamide hydroxamic acids
CN1646687A (zh) * 2002-03-14 2005-07-27 联邦科学和工业研究组织 修饰的基因沉默rna及其用途
EP1348943A3 (en) * 2002-03-25 2003-12-17 Sysmex Corporation Sheath liquid for particle analyzer
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US7387896B2 (en) * 2003-03-26 2008-06-17 The Regents Of The University Of Michigan MicroRNA vectors
DK2129680T3 (en) 2007-03-21 2015-08-10 Brookhaven Science Ass Llc COMBINED hairpin ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF

Also Published As

Publication number Publication date
PL2129680T3 (pl) 2015-10-30
ES2538217T3 (es) 2015-06-18
CA2681323A1 (en) 2008-09-25
US8796442B2 (en) 2014-08-05
EP2129680A4 (en) 2010-10-20
US9193972B2 (en) 2015-11-24
JP5759673B2 (ja) 2015-08-05
AU2008228814B2 (en) 2014-03-06
BRPI0809130A8 (pt) 2021-11-03
EP2129680A2 (en) 2009-12-09
US20140342453A1 (en) 2014-11-20
PT2129680E (pt) 2015-08-28
BRPI0809130A2 (pt) 2014-08-26
AR080722A2 (es) 2012-05-02
WO2008116094A3 (en) 2008-11-20
EP2129680B1 (en) 2015-05-06
US20080311658A1 (en) 2008-12-18
AU2008228814A1 (en) 2008-09-25
WO2008116094A2 (en) 2008-09-25
HUE027018T2 (en) 2016-08-29
JP2010521973A (ja) 2010-07-01
DK2129680T3 (en) 2015-08-10
AR066194A1 (es) 2009-08-05

Similar Documents

Publication Publication Date Title
AR080722A2 (es) Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica
SA519410164B1 (ar) (pkr) تركيبات البيرولوبيرول بوصفها منشطات كينازُ البيروفات
MX2026000627A (es) Transcripcion controlable
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
AR107242A1 (es) Preparación térmica de esporas bacterianas
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
PE20180743A1 (es) Metodo para produccion de l-aminoacido
MX2009007920A (es) Proceso y aparato para generar biocidas haloamina.
NZ726323A (en) Antimicrobial compositions
EA201890641A3 (ru) Стимуляторы sgc
ECSP14028704A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn
AR069980A1 (es) Inmunoconjugados dirigidos contra cd 138 y sus usos
MX2019006206A (es) Polimorfos de sepiapterina y sales de los mismos.
AR114504A1 (es) Regeneración de plantas genéticamente modificadas
MX2021013914A (es) Células, tejidos, órganos y/o animales que tienen uno o más genes modificados para supervivencia y/o tolerancia de xenoinjerto mejorada.
MX373157B (es) Metodos de extincion mejorados para la inactivacion de patogenos en globulos rojos.
MX2020003954A (es) Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
CL2011002518A1 (es) Proceso para producir un vegetal, una semilla o su progenie, basado en transformar células vegetales con una secuencia de ácido nucleico que codifica una proteína quinasa relacionada con snf1, vector que comprende dicha secuencia; y métodos de aplicación.
BR112021026002A2 (pt) Regeneração e transformação melhorada de plantas com a ajuda de um gene de reforço grf1
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
EP4650364A3 (en) Materials and methods for treatment of pain related disorders
AU2018337668A1 (en) Improved supraparticles
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
AU2017254665A1 (en) Compositions and methods for enhanced gene expression of pklr

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration